anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To provide novel strains of Lactococcus lactis subsp. cremoris capable of producing fermented food and drinks with less stringiness as ordinary fermented food and drinks while maintaining the flavor of Lactococcus lactis subsp. cremoris.SOLUTION: The invention relates to a lactic acid bacterium, Lactococcus lactis subsp. cremoris NITE P-02535 (Accession number: NITE P-02535), a composition, food and drink composition, pharmaceutical composition or a fermented food and drink those containing the lactic acid bacterium Lactococcus lactis subsp. cremoris NITE P-02535 (Accession number: NITE P-02535); and production methods thereof. A method for producing a fermented food and drink comprises adding Lactococcus lactis subsp. cremoris NITE P-02535 (Accession number: NITE P-02535) to a sterilized liquid milk formula comprising a milk raw material and conducting fermentation until pH becomes 5.0 or lower.SELECTED DRAWING: None
The intervention group will be asked to complete PROM questionnaires at baseline, 6 months, and 12 months via an online web-based delivery system. The treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group. Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
Surgical site antisepsis is critical in preventing surgical site infections. Although chlorhexidine gluconate has proven to be superior to povidone iodine for surgical site antisepsis, povidone iodine is the only FDA-approved antiseptic solution for surgical preparation of the vagina. Many surgeons are hesitant to use chlorhexidine gluconate for preoperative vaginal cleansing due to the alcohol dissolvent present in the solutions that is implicated in a greater risk of irritation. Yet, there has been no randomized study to illustrate whether the risk of vaginal irritation is greater in chlorhexidine gluconate versus povidone iodine. Thus, the purpose of the study is to conduct a randomized control trial to compare the tolerance of 4% chlorhexidine gluconate to povidone iodine using patient-reported outcomes of vaginal or urinary symptoms. Patients will be randomized to either control or experimental, and then be given a short survey prior to and immediately after surgery, and again 24-48 hours via phone asking them about the presence and severity of vaginal dryness, burning, itchiness, unusual vaginal discharge, and pain or burning with urination.
OBJECTIVES: Parainfluenza virus type 3 (PIV3) outbreaks among hematology patients are associated with high morbidity and mortality. Prompt implementation of infection prevention (IP) measures has proven to be the most efficacious approach for controlling PIV3 outbreaks within this patient population. The most suitable IP measures can vary depending on the mode of virus transmission, which remains unidentified in most outbreaks. We describe the molecular epidemiology of an outbreak of PIV3 among hematology patients and the development of a new method that allows for the differentiation of outbreak and community strains, from which a closed outbreak could be inferred.
METHODS: Patients were screened for respiratory viruses using multiplex-PCR. PIV3 positive samples with a cycle threshold (Ct)-value of <31 underwent a retrospective characterization via an in-house developed sequence analysis of the hemagglutinin-neuraminidase (HN) gene.
RESULTS: Between July and September 2022, 31 hematology patients were identified with PIV3. Although infection control measures were implemented, the outbreak persisted for nine weeks. Sequencing the HN gene of 27 PIV3 strains from 27 patients revealed that all outbreak strains formed a distinct cluster separate from the control strains, suggestive of a nosocomial transmission route.
CONCLUSIONS: Sequencing the HN gene of PIV3 strains in an outbreak setting enables outbreak strains to be distinguished from community strains. Early molecular characterization of PIV3 strains during an outbreak can serve as a tool in determining potential transmission routes. This, in turn, enables rapid implementation of targeted infection prevention measures, with the goal of minimizing the outbreak's duration and reducing associated morbidity and mortality.
Pregnancy Category C

There are no adequate and well-controlled studies in pregnant women.

Reproduction studies have been performed in mice, rats and rabbits. After oral administration of 14C-solifenacin succinate to pregnant mice, drug-related material was shown to cross the placental barrier. No embryotoxicity or teratogenicity was observed in mice treated with 1.2 times (30 mg/kg/day) the expected exposure at the maximum recommended human dose [MRHD] of 10 mg. Administration of solifenacin succinate to pregnant mice at 3.6 times and greater (100 mg/kg/day and greater) the exposure at the MRHD, during the major period of organ development resulted in reduced fetal body weights. Administration of 7.9 times (250 mg/kg/day) the MRHD to pregnant mice resulted in an increased incidence of cleft palate. In utero and lactational exposures to maternal doses of solifenacin succinate of 3.6 times (100 mg/kg/day) the MRHD resulted in reduced peripartum and postnatal survival, reductions in body weight gain, and delayed physical development (eye opening and vaginal patency). An increase in the percentage of male offspring was also observed in litters from offspring exposed to maternal doses of 250 mg/kg/day. No embryotoxic effects were observed in rats at up to 50 mg/kg/day (<1 times the exposure at the MRHD) or in rabbits at up to 1.8 times (50 mg/kg/day) the exposure at the MRHD. Because animal reproduction studies are not always predictive of human response, Solifenacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The technique for surgical endoscopic treatment of the primary congenital obstructive decompensated refluxing megaureter in the newborns and in the children aged below 5 years provides for the complex reconstructive two-stage surgical treatment. At the first stage, nephrostomy or T-shaped direct or inverse ureterocutaneostomy is performed, the antireflux protection of the ureter is carried out. At the first stage, the external drainage of the upper urinary tract is performed at the age of 1-3 years. Upon the recovery of the contractile ability of the ureter, the decrease in its diameter at least to 10 mm, and the improvement of the renal function and the renal hemodynamics, the antireflux endoscopic correction is performed by paraureteral implantation of polyacrylamide gel Intefal preparation with continuing external drainage of the upper urinary tract. The second stage of the treatment consists in recovery of the integrity of the urinary tract when the external drainage of the upper urinary tract is terminated. This stage is performed when the vesico-ureteral reflux is absent upon the endoscopic correction.
Pharmaceutical compositions for topical application comprise a carrier and a flavone or 2,3-dihydroflavone of general formula <FORM:0928150/VI/1> or <FORM:0928150/VI/2> wherein each of R1 to R10 may represent a hydrogen atom or a hydroxy radical or an alkoxy radical in which the alkyl group contains from 1 to 4 carbon atoms or an axyloxy radical in which the acyl group contains from 1 to 5 carbon atoms in admixture with a steroid of the pregnane (C21 nucleus) series having topical anti-inflammatory activity according to a specified test, e.g. cortisone, prednisone and prednisolone and derivatives thereof including halogen derivatives, alkali metal phosphates, hydrocarbon dicarboxylic acid 21-hemi-esters and their water-soluble salts, many specific examples of which are given. The compositions may be in conventional forms suitable for topical application, e.g. ointments, lotions, creams, nasal sprays, drops, suppositories, aerosols, and powders which may optionally also comprise antibiotics, e.g. neomycin, tetracyclines, novobiocin, erthromycin, penicillin, chloramphenicol, streptomycin, bacitracin, polymyxin, tyrothrycin and gramicidin; antifungal agents, e.g. iodochlorohydroxyquin, filipin and nystatin; vasoconstrictors, e.g. phenylephrine and isoproterenol and the local an sthetics, e.g. procaine, phenocaine, tetracaine, lidocaine, primoxine and ethylaminobenzoate.
The aim of this study was to analyze the pregnancy process, especially the Familial Mediterranean fever (FMF) disease course and attack types during pregnancy, and to examine the relationship between disease-related factors and female infertility in FMF patients. The study, which was planned in a multicenter national network, included 643 female patients. 435 female patients who had regular sexual intercourse were questioned in terms of infertility. Pregnancy and delivery history, FMF disease severity and course during pregnancy were evaluated. The relationship between demographic and clinical findings, disease severity, genetic analysis results and infertility was investigated. 401 patients had at least 1 pregnancy and 34 patients were diagnosed with infertility. 154 patients had an attack during pregnancy. 61.6% of them reported that attacks during pregnancy were similar to those when they were not pregnant. The most common attack symptoms were fever, fatigue and abdominal pain-peritonitis (96%, 87%, and 83%, respectively) in the pregnancy period. The disease-onset age, disease activity score, gene mutation analyses, and regular colchicine use (> 90%) were similar between the fertile and infertile groups, while the frequency of previous appendectomy and alcohol consumption rates were higher in individuals with infertility. Our results indicated no significant change in the frequency and severity of attacks during pregnancy. The low rate of infertility (7.8%) in our patients was noted. It has been suggested that the risk of FMF-related infertility may not be as high as thought in patients who are followed up regularly and received colchicine.
Non-muscle invasive bladder cancer (NMIBC) is one of the most common type of bladder cancer. Here, we have utilized an integrated transcriptomic-computational approach to identify alternate treatments to the NMIBC. In this study, we have performed the comprehensive comparative analysis between three groups of 36 patients with non-relapsed (NR), recurrence and progressive symptoms. Differentially expressed genes involved in the pathways associated with the NMIBC were identified. In silico protein-protein interaction (PPI) network was performed to create the network of the hub genes associated with NMIBC. Further, we compared NR individuals with two cohorts of patients with recurrent and progressive symptoms that lead to the identification of three major biomarkers CD34, FLT1 and WHSC1 genes. Concurrently, PPI also suggests that they are significant hub genes responsible for disease recurrence and progression. Furthermore, targeted genes WHSC-1 and FLT-1 were subjected to virtual screening for identification phytochemical inhibitors. Docking and molecular dynamics simulations concluded that the phytochemicals anonymously named 'UNK' and '6-hydroxycyanidin' are suitable for the inhibition of the proteins causing the NMIBC. In the future, this study will help for strengthening the strategies development at the molecular level for the control of carcinomas at early as well as detection of active and binding site, receptor-ligand interaction and also make drug designing for the early treatment of the carcinomas.Communicated by Ramaswamy H. Sarma.
<P>PROBLEM TO BE SOLVED: To provide an incense coil which eliminates a fear of dying of fire caused by contact between adjacent portions of the coil due to hanging of the coil in a high-humidity environment and due to hanging failure in a low-temperature low-humidity environment, and to provide a hanging fixture which enables the incense coil to stably hang from a hanger, brings about safe and spontaneous dying of fire at an innermost portion of the incense, is small in size, and easy to handle.  <P>SOLUTION: The incense coil having a circular cross section is formed such that a radial interval between the adjacent portions of the coil when laid horizontally standstill is larger than a cross-sectional width and smaller than three times the cross-sectional width. The hanging fixture for hanging the incense coil from the hanger is formed of a body consisting of a column portion and a collar portion, and a hanging means arranged at the center of an upper surface of the column portion. Then the innermost portion of the incense coil is laid on the collar portion so as to enclose the column portion, and then hung from the hanger. Herein the innermost portion of the incense coil laid on the collar portion is larger than 0.5 times a winding of the coil and smaller than 1.5 times the winding, as viewed from the center of the column portion.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present invention relates to a pill for treating cardiovascular and cerebrovascular diseases. The present invention is a pill preparation prepared from the following raw material medicine through pulverization: 40 to 60 parts by weight of notoginseng, 15 to 20 parts by weight of scorpion, 40 to 55 parts by weight of coptis, 20 to 40 parts by weight of honeysuckle flower, 40 to 60 parts by weight of lumbricus, 40 to 60 parts by weight of safflower, 9 to 15 parts by weight of rhizoma corydalis, 40 to 60 parts by weight of red sage root, 20 to 40 parts by weight of curcuma root, 40 to 60 parts by weight of hemlock parsley, 20 to 40 parts by weight of radix cyathulae, 45 to 60 parts by weight of hawthorn fruit, 40 to 60 parts by weight of angelica, 10 to 25 parts by weight of red peony root, 20 to 30 parts by weight of alismatis, 40 to 60 parts by weight of radix astragali, 80 to 150 parts by weight of wolfberry fruit, 10 to 20 parts by weight of prepared fleece flower root, 20 to 40 parts by weight of epimedium herb, 20 to 40 parts by weight of eucommia bark, 40 to 60 parts by weight of cortex acanthopanacis radices, 40 to 60 parts by weight of homalomena rhizoma, 15 to 20 parts by weight of papaya, 20 to 40 parts by weight of aucklandia root, 20 to 40 parts by weight of kudzu root, 20 to 40 parts by weight of rhizoma polygonati, 40 to 60 parts by weight of pagodatree flower bud, 40 to 60 parts by weight of radix paeoniae alba, 40 to 60 parts by weight of cassia bark and a right amount of beeswax. The pill has the efficacy of treating cardiovascular and cerebrovascular diseases and has the efficiency of improving the sexual function. Especially, the pill can prevent patients who have cardiovascular and cerebrovascular diseases from sudden death caused by onset of the symptom in sexual intercourse and can restore and strengthen the sexual function. The patients can safely spend sexual life through the pill. The pill also has the advantages of good effect and low.
Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
PURPOSE:To provide an agent for inhibiting aldose reductase, having strong aldose reductase inhibiting activity and useful for the prevention of the complicating diseases of diabetes, by using a flavone derivative as an active component. CONSTITUTION:The agent for inhibiting aldose reductase (AR) contains a flavone derivative selected from the compound of formula (R1 is H or OH; R2 is  OH or methoxy) and its salt. Since the complicating diseases of diabetes (e.g.  cataract, retinal diseases, renal diseases, etc.) are caused by the unnecessary  accumulation of polyols derived from saccharides by AR, it is necessary for the effective prevention of the diseases to inhibit the enzymatic activity of AR  which is the direct cause of the diseases. In the compounds of formula, 6, 3',  4'-trihydroxy-5, 7, 8-trimethoxyflavone, etc. have strong AR-activity inhibiting capability, and effectively prevent the complicating diseases of diabetes.
The safety and effectiveness of Fexinidazole Tablets for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) HAT due to Trypanosoma brucei gambiense have been established in pediatric patients aged 6 years and older and weighing at least 20 kg. Use of Fexinidazole Tablets for this indication is supported by evidence from an adequate and well-controlled trial in adults with additional efficacy, pharmacokinetic and safety data in pediatric patients aged 6 years and older [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14)].

Pediatric patients may be more sensitive to vomiting. The safety profile for Fexinidazole Tablets in pediatric patients was generally similar to that of adult patients with the exception of more frequent vomiting within 2 hours of administration of Fexinidazole Tablets. Vomiting did not result in permanent treatment discontinuation [see Adverse Reactions (6.1)].

The safety and efficacy of Fexinidazole Tablets have not been established in pediatric patients younger than 6 years old and/or less than 20 kg in body weight.
These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
A capsaicin and dihydrocapsaicin having therapeutic effect of diabetes and cardiovascular diseases related to obesity, obesity-induced inflammation and complication is provided to enhance the expression of adiponectin gene and protein secretion. A capsaicin or dihydrocapsaicin is used as a therapeutic agent of diabetes related to obesity, obesity-induced inflammation and complication and cardiovascular diseases. The capsaicin or dihydrocapsaicin acts for improving obesity-induced inflammation and complication through generation control of adipokine or adipocytokine from adipose tissue and adipocyte of mammal. Human is excluded from the mammal. The adipokine or adipocytokine is IL-6, TNF-alpha (tumor necrosis factor alpha), MCP-1, COX-2 (cycooxygenase-2), and adiponenctin. The capsaicin or dihydrocapsaicin inactivates the NF-Kb (neuclear factor kappa B) pathway, suppresses the movement of macrophage in obesity adipose tissue and improves inflammatory reaction of macrophage.
A plaster for treating hyperosteogeny bony spurs comprises Bunge Corydalis Herb, Seed of Garden Balsam, root of Nutgall Tree, Boswellia carteri, myrrh, Bark of Girald Daphne, Aconitum kusnezoffii, Japan Buttercup, Hindu Datura seed, mirabilite, Spina Gleditsiae, minium, Herba Speranskiae Tuberculatae, willow fungus and Gloeostereum incarnatum. A production method of the plaster comprises the following steps: boiling Bunge Corydalis Herb in water, filtering the obtained decoction, concentrating the filtered decoction through sequentially using strong fire and weak fire, adding medicinal powders formed by grinding remaining medicines when the obtained concentrate is clear and dilute and forms a fine line when being picked by chopsticks, and uniformly stirring. The production method solves the problem of destroy of too high temperature of oil frying to effective components in the traditional Chinese medicines), and can treat hyperosteogeny. The plaster is convenient for people to use, realizes health and no flowing, reduces patients' pains, and reduces the economy burden. Hyperosteogeny is treated by dispelling wind and cold, eliminating dampness and warming yang according to arthralgia in the traditional Chinese medicine field. Chinese medicine science and western medicine science are combined in the invention, and the causing reasons of hyperosteogeny, considered in the invention, are calcium deficiency, kidney vacuity and bone heat, so the hyperosteogeny is treated in the invention through combining supplementation and draining, clearing heat and reducing phlegm, softening hardness and detoxifying, reducing maxillary osteomyelitis fatigue, and strengthening bones and relieving exterior syndromes.
The anti-HIV agent nevirapine is associated with rapid emergence of resistance when administered alone or in combination with zidovudine to HIV-infected patients with CD4 counts \<= 400 cells/mm3. In persons with less advanced HIV disease and less viral burden, the emergence of resistance may be delayed, thus permitting evaluation for beneficial effect in a population where there is currently no established therapy.

Ten patients receive nevirapine daily for 12 weeks. After 12 weeks of therapy, patients in whom resistance was not evident at week 4 and who have an adequate safety profile continue receiving nevirapine for an additional 12 weeks. Clinical and immunological assessments are performed at weeks 4, 8, 12, 16, 20, and 24. Virological assessments are performed at week 24 only. If 50 percent of patients develop resistance at any time, the study is discontinued.
This was a prospective randomized controlled trial with parallel groups following the Consolidated Standards of Reporting Trials and was approved by the Institutional Review Board of Jianan Mental Health Hospital (approval number Taiwan Nurses Association-1012023/ 12-002). Informed consent was obtained from all the subjects. Patients who had been hospitalized for schizophrenia, schizophreniform disorder, and schizoaffective disorder for more than 5 years according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association, 2013) criteria were eligible to participate in the study. Patients who had a history of alcohol and drug abuse or could not concentrate on activities for at least 30 minutes were excluded from the study. As shown in the CONSORT diagram (Schulz et al., 2010), 109 patients were screened, 95 participants were enrolled by a research assistant and received interventions delivered by a nurse researcher. In the end, total 90 participants completely received multi-sensory stimulation therapy in a psychiatry institution in Southern Taiwan. None of the adverse events occurred. All patients were initially randomly assigned to either intervention or treatment as usual (TAU) group using a computer-generated random allocation sequence. The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffusers, music...etc.. The TAU group received usual routine care. After receiving either intervention or routine care, there was a 2-week washout period to clear the residual effects from the initial assigned group activities. Patients were then crossover into the other group where the process started over. Symptoms were assessed at baseline (T0), after the 1st session (T1), the 3rd session (T2) and the 6th session (T3). No important changes to the methods or trial outcomes were made after trial commencement.

Sample Size Calculation:

Sample size was calculated based on showing between group outcome differences after receiving MST according to a previous study (Cheng et al., 2017) of 60 patients who underwent the same comprehensive protocol. To achieve statistical significance p\< 0.05, each parallel group of our study required at least 30 patients.

All the outcome assessments were by original assigned groups. Descriptive analysis was conducted for analyzing demographics and outcomes in all time points. Repeated Measurement of Analysis of Variance (ANOVA) was used to examine the effectiveness of MST between experimental and control groups. Effect size was determined using partial η2 that reflects the percentage of the variance in outcome variables explained by the independent variables.